← DeepTechTracker
Molecular illustration accompanying the Isomorphic Labs Series C announcement.

Isomorphic Labs raises $5 billion to move AI-designed medicines toward trials

Illustration: Isomorphic Labs, from its official funding announcement.

Isomorphic Labs has announced a $5 billion Series C round co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz and other new investors joined, alongside further investment from Alphabet. Existing investors Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also participated, according to the company's 17 November announcement.

The London-headquartered company develops its own AI models for drug design. Its drug design engine, IsoDDE, combines simulation models that predict molecular behaviour across different diseases and types of medicine. Researchers use those predictions to search for and refine possible drug molecules before testing them experimentally. This is model and drug-development research, rather than a software application built only around someone else's AI service.

The money will support further development of IsoDDE, a larger pipeline of internal and partnered drug candidates, and the infrastructure needed to move candidates through translational research and clinical development. The company also plans to study new areas of biology and expand its global AI-led bioengineering infrastructure.

Isomorphic reports positive preclinical results in its own oncology and immunology programmes and in work with partners. Preclinical work comes before testing a candidate's safety and effectiveness in people. The funding announcement describes progress toward clinical trials, not a proven treatment or a medicine approved for patients. It does not give a new clinical-trial start date or disclose a valuation.

Founded in 2021, Isomorphic is led by founder and CEO Sir Demis Hassabis and president Max Jaderberg. Its announcement lists offices in Cambridge, Massachusetts, and Lausanne, Switzerland, in addition to its London headquarters. The financing backs both its underlying AI technology and the slower experimental and clinical work needed to turn a predicted molecule into a medicine.

Read at source ↗

Financing, investors, product, pipeline and leadership: official Isomorphic Labs announcement and full news release, 17 November 2026. Preclinical progress is company-reported. No valuation or new clinical-trial start date is disclosed in the release.

Additional reporting

What it does

Develops proprietary AI simulation models and a drug design engine to design and refine potential medicines.

Round

$5 billion Series C, co-led by Greenoaks and Sequoia Capital.

Leadership

Founder and CEO Sir Demis Hassabis; president Max Jaderberg.

Use of funds

Develop IsoDDE, expand internal and partnered drug candidates, and build translational, clinical and AI-led bioengineering infrastructure.

Base

London, United Kingdom.

Stage boundary

Company-reported preclinical results; advancing candidates toward clinical trials, not approved medicines.

Browse more DeepTech news →

Who's raising. Who's funding. What's next in DeepTech.